OncRef

Clinical Trial: NCT04419402

Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 2

Lead Sponsor:Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Information Provided By:Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Last Update Posted:2026-06-22

Study Overview

Brief Summary

This phase 2 randomised clinical trial will investigate the activity and safety of adding Lu-PSMA to enzalutamide in patients with metastatic castrate resistant prostate cancer (mCRPC) not previously treated with chemotherapy.

Official Title

ENZA-p: A Randomised Phase II Trial Using PSMA as a Therapeutic Agent and Prognostic Indicator in Men With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide (ANZUP 1901)

Conditions

Metastatic Castration-Resistant Prostate Cancer

Intervention / Treatment

  • Drug: Lu-PSMA
  • Drug: Enzalutamide

Other Study ID Numbers

  • ANZUP 1901

Start Date (Actual)

2020-08-17

Primary Completion Date (Actual)

2024-04-12

Study Completion Date (Estimated)

2026-12-01

Enrollment (Actual)

162

Study Type

Interventional

Phase

Phase 2